Silver Book Fact

About 1/2 of the decrease in recent deaths in cardiovascular disease can be attributed to medical treatment.

Ford E, Ajani U, Croft J, Critchley J, et al. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980-2000. New England Journal of Medicine. June 2007; 356: 2388-98. http://content.nejm.org/cgi/content/abstract/356/23/2388

Reference

Title
Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980-2000
Publication
New England Journal of Medicine
Publication Date
June 2007
Authors
Ford E, Ajani U, Croft J, Critchley J, et al.
Pages
2388-98
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Following the current path, pulmonary condition cases will increase by 31.3% between 2003 and 2023. If an alternative path is taken, there will be 9.1% fewer pulmonary condition cases.  
  • If all forms of cardiovascular disease were eliminated, life expectancy would rise by almost 7 years.  
  • TAVR improves quality of life in SAS patients
     
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…